uniQure N.V.QURE
What uniQure N.V. does.
We are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. We are advancing a focused pipeline of innovative gene therapies, including our clinical candidates for the treatment of Huntington’s disease, refractory mesial temporal lobe epilepsy (“MTLE”), Fabry disease, and amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 (“SOD1-ALS”).
In September 2025, we announced p ositive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington’s disease. We analyzed clinical outcomes for 29 patients treated with AMT-130 (n=17 high-dose; n=12 low-dose) of which 12 patients per dose group had attained 36 months of follow-up and were evaluated at that time point. Outcomes for each dose group were compared to a propensity score-matched external control drawn from the Enroll-HD natural history data set (n=940 for high-dose; n=626 for low-dose).
Topline 36-month efficacy results for patients receiving high-dose AMT-130 were as follows (data cutoff as of June 30, 2025):
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $37.5M | $524.0M | $106.5M | $15.8M | $27.1M | $16.1M |
| Net income | -$125.0M | $329.6M | -$126.8M | -$308.5M | -$239.6M | -$199.0M |
| Free cash flow | -$142.1M | $270.5M | -$162.7M | -$153.1M | -$186.1M | -$178.4M |
More on QURE.
- uniQure N.V. summary
- uniQure N.V. financial statements
- uniQure N.V. key metrics
- uniQure N.V. health scores and style box
- uniQure N.V. earnings
- uniQure N.V. dividends
- uniQure N.V. valuation
- uniQure N.V. ownership and insiders
- uniQure N.V. peers
Figures from uniQure N.V.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.